With 3.0 million shares changed hands, the volume of the stock remained lighter than its average volume of 5.32 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.65 whereas the lowest price it dropped to was $0.495. The 52-week range on ONCO shows that it touched its highest point at $21.40 and its lowest point at $0.32 during that stretch. It currently has a 1-year price target of $360.00. Beta for the stock currently stands at 3.20.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ONCO was up-trending over the past week, with a rise of 38.24%, but this was down by -4.11% over a month. Three-month performance dropped to -87.82% while six-month performance fell -89.87%. The stock lost -91.78% in the past year, while it has lost -4.11% so far this year.
Float and Shares Shorts:
At present, 8.31 million ONCO shares are outstanding with a float of 3.50 million shares on hand for trading. On 2024-11-15, short shares totaled 33333.0, which was 40.0 higher than short shares on 1728950400. In addition to Dr. Ralph Schiess Ph.D. as the firm’s Interim CEO & Chief Science Officer, Ms. Karina M. Fedasz serves as its Interim Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.07863 of ONCO’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, ONCO reported revenue of $406859.0 and operating income of -$2645867.0. The EBITDA in the recently reported quarter was -$3325234.0 and diluted EPS was -$2.93.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
Analysts have provided yearly estimates in a range of -$34 being high and -$34 being low. For ONCO, this leads to a yearly average estimate of -$34.
